CombinatoRx Abstract Accepted for Oral Presentation at EULAR 2009

-- Synavive (CRx-102) Phase 2 Trial (COMET-1) Clinical Results to be Presented
--
CAMBRIDGE, Mass.--(Business Wire)--
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that its abstract,
"CRx-102, a dissociated glucocorticoid (GC), and prednisolone provide safe and
effective pain relief in knee osteoarthritis (OA) in a placebo-controlled Phase
2 trial (COMET-1)", has been accepted for oral presentation at EULAR 2009, the
Annual European Congress of Rheumatology in Copenhagen on June 12, 2009. The
abstract can be accessed online at www.eular.org: click on "EULAR Congress 2009"
and "abstracts", and enter the search term or abstract number. The abstract will
also be published in the congress abstract book, a supplement to "Annals of
Rheumatic Diseases - the EULAR Journal".

Oral Presentation:

-- Abstract OP-0212, "CRx-102, a dissociated glucocorticoid (GC), and
prednisolone provide safe and effective pain relief in knee osteoarthritis (OA)
in a placebo-controlled Phase 2 trial (COMET-1)", Shergy, et.al, has been
accepted for oral presentation by Kenneth Huttner, MD on Friday, June 12, 2009:
10:15-11:45 AM during Osteoarthritis-Clinical Advances session in Room C1.

About CombinatoRx:

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic
combination pharmaceuticals. Going beyond traditional combinations, CombinatoRx
creates product candidates with novel mechanisms of action, striking at the
biological complexities of human disease. The CombinatoRx proprietary drug
discovery technology provides a renewable and previously untapped source of
novel drug candidates. The Company was founded in 2000 and is located in
Cambridge, Massachusetts. To learn more about CombinatoRx, please visit
www.combinatorx.com.

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its
product candidate Synavive and its clinical potential, its drug discovery
technology, and business plans. These forward-looking statements about future
expectations, plans and prospects of CombinatoRx involve significant risks,
uncertainties and assumptions, including risks related to the unproven nature of
the CombinatoRx drug discovery technology, the Company's ability to initiate and
successfully complete clinical trials of Synavive, potential difficulty and
delays in obtaining regulatory approval for the sale and marketing of Synavive
and those other risks that can be found in the "Risk Factors" section of the
CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange
Commission and the other reports that CombinatoRx periodically files with the
Securities and Exchange Commission. Actual results may differ materially from
those CombinatoRx contemplated by these forward-looking statements. These
forward looking statements reflect management`s current views and CombinatoRx
does not undertake to update any of these forward-looking statements to reflect
a change in its views or events or circumstances that occur after the date of
this release.

(c) 2009 CombinatoRx, Incorporated. All rights reserved.

CombinatoRx, Incorporated
Robert Forrester, 617-301-7100
Executive Vice President, Chief Financial Officer
rforrester@combinatorx.com
or
CombinatoRx, Incorporated
Gina Nugent, 857-753-6562
gnugent@combinatorx.com

Copyright Business Wire 2009